US equities |
NVDA $241.52 ▲+1.10% SPCX $174.25 ▲+1.84% MU $1,066.09 ▲+0.20% AMD $656.90 ▲+3.98% MRVL $292.06 ▲+7.67% SNDK $1,670.37 ▼-1.98% AVGO $378.60 ▲+4.44% TSLA $380.95 ▲+0.59%
FinancialContent

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

3.720 +0.010 (+0.27%)
Delayed Quote Updated: 11:53 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also... 
Via Benzinga
News headline image
FDA Slams Break On Fulcrum Therapeutics' Sickle Cell Disease Study, Shares Plummet ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News ↗
FULC stock is falling fast today due to a regulatory issue, but Fulcrum Therapeutics remains committed to combating sickle cell disease. 
Via InvestorPlace
News headline image
US Stocks Open Lower; Dow Drops 1% ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
Expert Ratings for Fulcrum Therapeutics ↗
 
Via Benzinga
News headline image
Why Fulcrum Therapeutics Shares Are Falling ↗
Fulcrum Therapeutics Inc (NASDAQ: FULC) shares are trading lower by 6.43% to $13.09 Wednesday morning after the company announced pricing of an upsized public offering of common stock. 
Via Benzinga
Looking Into Fulcrum Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
The Week In Charts - Becoming A Successful Trader ↗
Dave discusses various topics, including intra-day trading and trading opening gap reversals, the current stock market conditions, and his two cents on your favorite stock picks. 
Via Talk Markets
News headline image
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
$3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed sharply higher on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces CEO Transition
Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum, is appointed as interim CEO as Bryan Stuart departs to pursue other opportunities 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Earnings Preview ↗
Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum... 
Via Benzinga
News headline image
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >